Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

  • Awaiting development
  • GID-TA10916
  • Expected publication date: TBC

Status:
Awaiting development
Decision:
None selected
Process:
TA
ID number:
4017

For further information on our processes and methods, please see our CHTE processes and methods manual